1
龙沙集团
龙沙集团是全球最大的合同研发与生产组织（CDMO），也是全球细胞与基因治疗（CGT）行业的基础性制造合作伙伴。2025年，龙沙实现营收65.3亿瑞士法郎（约合74亿美元），EBITDA利润率达31.6%。该公司在其荷兰赫伦工厂赢得CASGEVY商业化生产合同，成为首个同时获得FDA、EMA和MHRA批准生产CRISPR疗法的工厂，这一成就具有里程碑意义。
优势：覆盖五大洲30多个设施的全球制造基…
十大基因与细胞治疗制造商及供应商排行
全球基因与细胞治疗（CGT）制造行业正经历一场根本性变革，从早期临床生产转向大规模商业化制造，部分单体设施的年产能已超过1万名患者。
CGT制造的经济格局在2025年被彻底改写。全球最大的CDMO——Lonza Group，营收达74亿美元，EBITDA利润率为31.6%，并独家拿下了CASGEVY的商业化生产合同。Kite Pharma通过其四大内部生产基地网络，实现了14天从采血到回输的周转周期。Legend Biotech位于Raritan的超级工厂产能已达1万名患者。药明康德的TIDES寡核苷酸产能突破10万升，同比增长96%。《BIOSECURE法案》从根本上重组了全球供应链，典型例证便是Minaris Advanced Therapies由药明康德ATU资产重组而成。本报告评估了全球CGT生产中占据主导地位的10家制造商。
<…前十榜单
2026.07 版本2
赛默飞世尔科技公司
Thermo Fisher Scientific Inc. 是全球领先的科学服务提供商，总部位于美国马萨诸塞州沃尔瑟姆。公司通过生命科学、分析仪器、专业诊断以及实验室产品与服务四大业务板块，为全球制药和生物技术公司、研究机构及临床实验室提供从基础研究到临床应用的完整工作流程解决方案。2025财年，赛默飞世尔营收约500亿美元，已成为支撑全球生命科学和医疗保健领域创新的基础设施合作伙伴。这一成就得益于其端到端"从样本到洞察"产品和服务组合所带来的强大客户粘性、在高端分析仪器和生命科学工具领域…
核心产品品类
仪器仪表测量检测仪器行业能源化工设备行业实验室设备行业医疗诊断设备行业体外诊断设备行业仪器仪表测量检测仪器行业能源化工设备行业实验室设备行业仪器仪表测量检测仪器行业能源化工设备行业实验室设备行业医疗诊断设备行业体外诊断设备行业仪器仪表测量检测仪器行业能源化工设备行业实验室设备行业
3
凯特制药（吉利德科学）
Kite Pharma是吉利德科学的全资子公司，在CAR-T细胞疗法商业化领域拥有无可争议的全球领先地位。其旗舰产品Yescarta在2025年实现15亿美元营收，Tecartus贡献3.44亿美元。Kite在美国和欧洲运营着四家完全自有的GMP认证细胞疗法生产基地，实现了仅14天的静脉到静脉周转时间。
优势：全球规模最大的CAR-T专用生产基础设施；FDA取消…
品牌
凯特制药（吉利德科学）
成立时间
2009
员工规模
2000+ (Kite) / 1.8万+ (Gilead)
覆盖范围
覆盖35+个国家
生产基地
4国5+自有细胞治疗超级工厂
总部
美国
市场
纳斯达克：GILD
4
百时美施贵宝（Bristol-Myers Squibb）公司
百时美施贵宝已构建起一个聚焦于免疫肿瘤、血液学及心血管领域的、高价值的生物制药生产网络，在12家自有生产设施中，2025财年营收约为468亿美元。该公司的生产运营围绕其三大治疗领域展开：肿瘤领域——通过大规模CHO细胞培养和多柱色谱纯化生产PD-1抑制剂Opdivo（纳武利尤单抗），通过患者特异性自体细胞处理生产CAR-T细胞疗法Breyanzi和Abecma，以及生产靶向小分子药物；血液学领域——尽管面临显著的仿制药侵蚀，仍通过复杂小分子合成生产Revl…
核心产品品类
生物医药品牌生物制品与疫苗行业癌症免疫治疗行业生长及罕见病生物制品行业自身免疫及炎症性疾病生物制品行业抗感染生物制剂行业生物医药工厂生物制品与疫苗行业癌症免疫治疗行业生长及罕见病生物制品行业生物医药品牌生物制品与疫苗行业癌症免疫治疗行业生长及罕见病生物制品行业自身免疫及炎症性疾病生物制品行业抗感染生物制剂行业生物医药工厂生物制品与疫苗行业癌症免疫治疗行业生长及罕见病生物制品行业
5
药明康德
药明康德是全球领先的CRDMO企业，也是TIDES（寡核苷酸与多肽）药物原料的领军生产商。2025年，药明康德实现营收454.6亿元人民币（63.5亿美元），其中TIDES业务同比增长96%，达到113.7亿元人民币。公司TIDES生产产能已达到10万升固相多肽合成能力，使其成为全球最大的寡核苷酸与多肽原料药制造商。
优势：在寡核苷酸与多肽合成领域占据主导市场地位，服务于基因治…
6
传奇生物
传奇生物已成为全球最成功的细胞治疗公司之一，其靶向BCMA的CAR-T疗法CARVYKTI在2025年实现全球终端用户销售额约19亿美元。该公司录得6.27亿美元确认收入，已为全球18个市场的超过1万名患者提供治疗。与强生公司的合作使其得以快速推进全球商业扩张及产能建设。
优势：CARVYKTI凭借高完全缓解率展现卓越临床数据；成功拓展至多发性骨髓瘤更早期治疗线…
7
诺华制药集团
诺华制药实施了制药行业最具特色的制造转型——剥离山德士高产量、低复杂度的仿制药生产，将其全球33个生产基地完全集中于先进治疗平台，在这些领域，生产复杂性构筑了持久的竞争护城河。公司2025财年净销售额达到545亿美元，核心创新药物包括可善挺（免疫学领域45亿美元）、诺欣妥（心血管领域35亿美元）以及快速增长的放射性药物业务。诺华的制造差异化战略体现在三大制造范式的领先地位，这些领域是仿制药CDMO无法经济复制的：放射性配体疗法生产——运营区域性生产设施网络…
核心产品品类
生物医药品牌化学药品制剂行业心血管及血液药物行业抗糖尿病药物行业生物制品与疫苗行业癌症免疫治疗行业生物医药工厂化学药品制剂行业心血管及血液药物行业抗糖尿病药物行业生物医药品牌化学药品制剂行业心血管及血液药物行业抗糖尿病药物行业生物制品与疫苗行业癌症免疫治疗行业生物医药工厂化学药品制剂行业心血管及血液药物行业抗糖尿病药物行业
8
丹纳赫公司
Danaher Corporation是一家全球领先的科技产品与服务提供商，总部位于美国华盛顿特区。公司业务聚焦于三大板块：生命科学、诊断以及环境与应用解决方案。通过一系列战略性收购与整合，公司构建了涵盖高端分析仪器、临床诊断系统及工业测量设备的多元化产品组合。2025财年，Danaher实现营收约320亿美元，成为通过系统化运营创造价值的典范。这一成就得益于其著名的“Danaher Business System”（DBS
核心产品品类
仪器仪表测量检测仪器行业能源化工设备行业实验室设备行业医疗诊断设备行业体外诊断设备行业仪器仪表测量检测仪器行业能源化工设备行业实验室设备行业仪器仪表测量检测仪器行业能源化工设备行业实验室设备行业医疗诊断设备行业体外诊断设备行业仪器仪表测量检测仪器行业能源化工设备行业实验室设备行业
9
金斯瑞生物科技
金斯瑞生物科技已在基因合成与细胞基因治疗CDMO市场确立主导地位，2025年实现营收9.595亿美元，同比增长61.4%，表现极为突出。其ProBio CDMO子公司营收实现爆发式增长309.1%至3.887亿美元，主要得益于质粒DNA、病毒载体生产及基因合成服务的需求激增。金斯瑞独特的生态系统模式——涵盖母公司基因合成业务、ProBio CDMO以及传奇生物（细胞治疗）——构建了完整的细胞基因治疗价值链。
优势：
10
赛多利斯集团
赛多利斯是一家领先的国际制药与实验室设备供应商，为细胞与基因治疗（CGT）制造提供关键的一次性生物工艺技术。2025年，赛多利斯实现营收约35.4亿欧元（38亿美元），并拥有强劲的29.7% EBITDA利润率。其一次性生物反应器系统和过滤技术已成为无菌CGT生产的行业标准。
优势：在CGT一次性生物工艺领域占据市场领先地位；29.7% EBI…
常见问题
基因和细胞治疗制造商是如何排名的？
我们的制造排名基于客观的生产数据和设施级分析，而非主观意见。VerityRank使用专有的综合评分（0-100分）对CGT制造商进行评估，涵盖四个加权维度。
生产规模与基础设施（30%）：这是权重最高的维度，反映了CGT制造的资本密集型特性。我们评估总GMP认证制造面积（平方英尺）、专用CGT生产套间数量、生物反应器容量（总升数）以及设施的地理分布。龙沙在五大洲拥有30多个设施，并独家持有CASGEVY商业制造合同，体现了我们所衡量的基础设施领导力。
技术集成（25%）：我们评估自动化采用、封闭系统处理能力以及AI驱动质量系统的实施情况。Cytiva（丹纳赫）的Sefia自动化细胞治疗平台和金斯瑞/ProBio的“黑灯工厂”代表了这一维度的前沿水平。
供应链控制（25%）：公司根据原材料采购的垂直整合、内部制造与外包制造的平衡、跨区域供应链冗余以及地缘政治韧性进行评分。赛默飞世尔科技在内部CGT耗材（Gibco培养基、Patheon CDMO、Brammer Bio载体）方面拥有无与伦比的广度，体现了深度的供应链整合。
法规合规与质量（20%）：我们追踪FDA/EMA/PMDA检查结果、商业制造批准历史、警告信和483表格记录，以及包括批次失败率在内的质量指标。所有数据均来自监管机构注册、2025财年文件以及公开可用的检查数据库。
生产规模与基础设施（30%）：这是权重最高的维度，反映了CGT制造的资本密集型特性。我们评估总GMP认证制造面积（平方英尺）、专用CGT生产套间数量、生物反应器容量（总升数）以及设施的地理分布。龙沙在五大洲拥有30多个设施，并独家持有CASGEVY商业制造合同，体现了我们所衡量的基础设施领导力。
技术集成（25%）：我们评估自动化采用、封闭系统处理能力以及AI驱动质量系统的实施情况。Cytiva（丹纳赫）的Sefia自动化细胞治疗平台和金斯瑞/ProBio的“黑灯工厂”代表了这一维度的前沿水平。
供应链控制（25%）：公司根据原材料采购的垂直整合、内部制造与外包制造的平衡、跨区域供应链冗余以及地缘政治韧性进行评分。赛默飞世尔科技在内部CGT耗材（Gibco培养基、Patheon CDMO、Brammer Bio载体）方面拥有无与伦比的广度，体现了深度的供应链整合。
法规合规与质量（20%）：我们追踪FDA/EMA/PMDA检查结果、商业制造批准历史、警告信和483表格记录，以及包括批次失败率在内的质量指标。所有数据均来自监管机构注册、2025财年文件以及公开可用的检查数据库。
How are gene and cell therapy manufacturers ranked?
Our manufacturing rankings are built on objective production data and facility-level analysis, not subjective opinions. VerityRank evaluates CGT manufacturers using a proprietary Composite Score (0-100) across four weighted dimensions.
Production Scale & Infrastructure (30%): This is the most heavily weighted dimension, reflecting the capital-intensive nature of CGT manufacturing. We assess total GMP-certified manufacturing footprint (square footage), number of dedicated CGT production suites, bioreactor capacity (total liters), and geographic distribution of facilities. Lonza, with 30+ facilities across five continents and the exclusive CASGEVY commercial manufacturing contract, exemplifies the infrastructure leadership we measure.
Technological Integration (25%): We evaluate automation adoption, closed-system processing capabilities, and implementation of AI-driven quality systems. Cytiva (Danaher)'s Sefia automated cell therapy platform and GenScript/ProBio's Lights-out factories represent the cutting edge of this dimension.
Supply Chain Control (25%): Companies are scored on vertical integration of raw material sourcing, in-house versus outsourced manufacturing balance, supply chain redundancy across regions, and geopolitical resilience. Thermo Fisher Scientific's unparalleled breadth of in-house CGT consumables (Gibco media, Patheon CDMO, Brammer Bio vectors) exemplifies deep supply chain integration.
Regulatory Compliance & Quality (20%): We track FDA/EMA/PMDA inspection outcomes, commercial manufacturing approval history, warning letter and Form 483 records, and quality metrics including batch failure rates. All data is sourced from regulatory establishment registrations, 2025 fiscal year filings, and publicly available inspection databases.
Production Scale & Infrastructure (30%): This is the most heavily weighted dimension, reflecting the capital-intensive nature of CGT manufacturing. We assess total GMP-certified manufacturing footprint (square footage), number of dedicated CGT production suites, bioreactor capacity (total liters), and geographic distribution of facilities. Lonza, with 30+ facilities across five continents and the exclusive CASGEVY commercial manufacturing contract, exemplifies the infrastructure leadership we measure.
Technological Integration (25%): We evaluate automation adoption, closed-system processing capabilities, and implementation of AI-driven quality systems. Cytiva (Danaher)'s Sefia automated cell therapy platform and GenScript/ProBio's Lights-out factories represent the cutting edge of this dimension.
Supply Chain Control (25%): Companies are scored on vertical integration of raw material sourcing, in-house versus outsourced manufacturing balance, supply chain redundancy across regions, and geopolitical resilience. Thermo Fisher Scientific's unparalleled breadth of in-house CGT consumables (Gibco media, Patheon CDMO, Brammer Bio vectors) exemplifies deep supply chain integration.
Regulatory Compliance & Quality (20%): We track FDA/EMA/PMDA inspection outcomes, commercial manufacturing approval history, warning letter and Form 483 records, and quality metrics including batch failure rates. All data is sourced from regulatory establishment registrations, 2025 fiscal year filings, and publicly available inspection databases.
顶级CGT制造商的五大基本能力是什么？
领先的CGT制造商通过五大核心生产能力脱颖而出，这些能力构成了难以逾越的进入壁垒。
大规模无菌处理：顶级制造商运营ISO 5级（A级）洁净室，配备自动化灌装线，每年可处理数千个患者特异性批次。位于荷兰赫伦的Lonza工厂同时为全球市场生产CASGEVY，并获得了FDA、EMA和MHRA的认证——这是全球首个获得CRISPR疗法三重监管批准的工厂。
病毒载体制造专长：以高滴度和纯度生产临床和商业数量的慢病毒和AAV载体的能力是一个关键差异化因素。Kite Pharma和百时美施贵宝运营着专用的内部病毒载体设施，而药明康德已扩大质粒和载体产能，以支持全球数十个临床项目。
封闭系统自动化：采用如Cytiva的Sefia系统等平台，可将人工干预减少80%，降低污染风险并提高批次一致性。赛默飞的Gibco CTSTM自动化组合和赛多利斯的Ambr自动化生物反应器系统进一步推动了从手动到自动化处理的转变。
供应链冗余：多洲制造布局确保生产连续性。Lonza在全球运营30多个工厂，赛默飞拥有数百个生产和分销站点，诺华在三大洲设有七个专用CGT设施。
质量源于设计（QbD）整合：将质量体系嵌入整个制造过程，而非仅依赖最终产品测试，可实现实时放行并降低批次失败率。丹纳赫/Cytiva的过程分析技术（PAT）平台和赛多利斯的集成数据分析支持了这一范式转变。
大规模无菌处理：顶级制造商运营ISO 5级（A级）洁净室，配备自动化灌装线，每年可处理数千个患者特异性批次。位于荷兰赫伦的Lonza工厂同时为全球市场生产CASGEVY，并获得了FDA、EMA和MHRA的认证——这是全球首个获得CRISPR疗法三重监管批准的工厂。
病毒载体制造专长：以高滴度和纯度生产临床和商业数量的慢病毒和AAV载体的能力是一个关键差异化因素。Kite Pharma和百时美施贵宝运营着专用的内部病毒载体设施，而药明康德已扩大质粒和载体产能，以支持全球数十个临床项目。
封闭系统自动化：采用如Cytiva的Sefia系统等平台，可将人工干预减少80%，降低污染风险并提高批次一致性。赛默飞的Gibco CTSTM自动化组合和赛多利斯的Ambr自动化生物反应器系统进一步推动了从手动到自动化处理的转变。
供应链冗余：多洲制造布局确保生产连续性。Lonza在全球运营30多个工厂，赛默飞拥有数百个生产和分销站点，诺华在三大洲设有七个专用CGT设施。
质量源于设计（QbD）整合：将质量体系嵌入整个制造过程，而非仅依赖最终产品测试，可实现实时放行并降低批次失败率。丹纳赫/Cytiva的过程分析技术（PAT）平台和赛多利斯的集成数据分析支持了这一范式转变。
What are the five essential capabilities of top CGT manufacturers?
Leading CGT manufacturers distinguish themselves through five core production capabilities that create formidable barriers to entry.
Large-Scale Aseptic Processing: Top manufacturers operate ISO Class 5 (Grade A) cleanrooms with automated filling lines capable of processing thousands of patient-specific batches annually. Lonza's Geleen, Netherlands facility simultaneously produces CASGEVY for global markets under FDA, EMA, and MHRA certification — the first facility globally to achieve this triple regulatory approval for a CRISPR therapy.
Viral Vector Manufacturing Expertise: The ability to produce clinical and commercial quantities of lentiviral and AAV vectors at high titers and purity is a critical differentiator. Kite Pharma and Bristol Myers Squibb run dedicated in-house viral vector facilities, while WuXi AppTec has expanded plasmid and vector capacity to support dozens of clinical programs globally.
Closed-System Automation: Implementation of platforms like Cytiva's Sefia system reduces manual intervention by 80%, lowering contamination risks and increasing batch consistency. Thermo Fisher's Gibco CTSTM automation portfolio and Sartorius' Ambr automated bioreactor systems further enable this transition from manual to automated processing.
Supply Chain Redundancy: Multi-continent manufacturing footprints ensure production continuity. Lonza operates 30+ facilities globally, Thermo Fisher maintains hundreds of production and distribution sites, and Novartis has seven dedicated CGT facilities across three continents.
Quality by Design (QbD) Integration: Embedding quality systems throughout the manufacturing process, rather than relying solely on end-product testing, enables real-time release and reduced batch failure rates. Danaher/Cytiva's process analytical technology (PAT) platforms and Sartorius' integrated data analytics enable this paradigm shift.
Large-Scale Aseptic Processing: Top manufacturers operate ISO Class 5 (Grade A) cleanrooms with automated filling lines capable of processing thousands of patient-specific batches annually. Lonza's Geleen, Netherlands facility simultaneously produces CASGEVY for global markets under FDA, EMA, and MHRA certification — the first facility globally to achieve this triple regulatory approval for a CRISPR therapy.
Viral Vector Manufacturing Expertise: The ability to produce clinical and commercial quantities of lentiviral and AAV vectors at high titers and purity is a critical differentiator. Kite Pharma and Bristol Myers Squibb run dedicated in-house viral vector facilities, while WuXi AppTec has expanded plasmid and vector capacity to support dozens of clinical programs globally.
Closed-System Automation: Implementation of platforms like Cytiva's Sefia system reduces manual intervention by 80%, lowering contamination risks and increasing batch consistency. Thermo Fisher's Gibco CTSTM automation portfolio and Sartorius' Ambr automated bioreactor systems further enable this transition from manual to automated processing.
Supply Chain Redundancy: Multi-continent manufacturing footprints ensure production continuity. Lonza operates 30+ facilities globally, Thermo Fisher maintains hundreds of production and distribution sites, and Novartis has seven dedicated CGT facilities across three continents.
Quality by Design (QbD) Integration: Embedding quality systems throughout the manufacturing process, rather than relying solely on end-product testing, enables real-time release and reduced batch failure rates. Danaher/Cytiva's process analytical technology (PAT) platforms and Sartorius' integrated data analytics enable this paradigm shift.
领先的CGT制造商实施哪些质量控制体系？
顶级CGT制造商维护着六种相互关联的质量控制系统，这些系统对患者安全和法规合规至关重要。
原材料鉴定：全面的供应商审计以及对关键原材料（包括细胞培养基（Gibco、Lonza）、细胞因子、病毒载体和冷冻保存溶液）的逐批检测。Thermo Fisher和Lonza提供具有完整可追溯性文档的认证原材料。
过程控制（IPC）：实时监控关键工艺参数，包括细胞活力、扩增率、转导效率和无菌性。Danaher/Cytiva的PAT平台可在整个制造过程中实现连续监控，将偏差检测到纠正措施的时间从几天缩短到几分钟。
环境监测：在ISO 5至ISO 8洁净室环境中进行连续粒子计数、微生物采样和HVAC验证。Kite Pharma的四个设施网络在所有生产套件中维持严格的环境监测计划。
产品放行检测：根据USP、EP和JP药典标准，进行全面的表征，包括无菌性、支原体、内毒素、效力、鉴别、纯度和安全性检测。WuXi AppTec的综合检测服务支持数百个客户项目的放行检测。
稳定性监测：实时和加速稳定性研究，确保产品从工厂到患者床边的整个低温冷链中的完整性。Sartorius提供冷冻保存和冷链监测解决方案，对这一质量维度至关重要。
批次处置和可追溯性：从单采到最终产品放行的完整监管链和身份链文档。Legend Biotech的专有跟踪系统确保每剂自体CARVYKTI从患者细胞采集到输注均可追溯，满足FDA对30年记录保存的要求。
原材料鉴定：全面的供应商审计以及对关键原材料（包括细胞培养基（Gibco、Lonza）、细胞因子、病毒载体和冷冻保存溶液）的逐批检测。Thermo Fisher和Lonza提供具有完整可追溯性文档的认证原材料。
过程控制（IPC）：实时监控关键工艺参数，包括细胞活力、扩增率、转导效率和无菌性。Danaher/Cytiva的PAT平台可在整个制造过程中实现连续监控，将偏差检测到纠正措施的时间从几天缩短到几分钟。
环境监测：在ISO 5至ISO 8洁净室环境中进行连续粒子计数、微生物采样和HVAC验证。Kite Pharma的四个设施网络在所有生产套件中维持严格的环境监测计划。
产品放行检测：根据USP、EP和JP药典标准，进行全面的表征，包括无菌性、支原体、内毒素、效力、鉴别、纯度和安全性检测。WuXi AppTec的综合检测服务支持数百个客户项目的放行检测。
稳定性监测：实时和加速稳定性研究，确保产品从工厂到患者床边的整个低温冷链中的完整性。Sartorius提供冷冻保存和冷链监测解决方案，对这一质量维度至关重要。
批次处置和可追溯性：从单采到最终产品放行的完整监管链和身份链文档。Legend Biotech的专有跟踪系统确保每剂自体CARVYKTI从患者细胞采集到输注均可追溯，满足FDA对30年记录保存的要求。
What quality control systems do leading CGT manufacturers implement?
Top CGT manufacturers maintain six interconnected quality control systems that are essential for patient safety and regulatory compliance.
Raw Material Qualification: Comprehensive supplier auditing and lot-to-lot testing of critical raw materials including cell culture media (Gibco, Lonza), cytokines, viral vectors, and cryopreservation solutions. Thermo Fisher and Lonza provide certified raw materials with complete traceability documentation.
In-Process Control (IPC): Real-time monitoring of critical process parameters including cell viability, expansion rates, transduction efficiency, and sterility. Danaher/Cytiva's PAT platforms enable continuous monitoring throughout the manufacturing process, reducing the time between deviation detection and corrective action from days to minutes.
Environmental Monitoring: Continuous particle counting, microbial sampling, and HVAC validation across ISO 5 through ISO 8 cleanroom environments. Kite Pharma's four-facility network maintains stringent environmental monitoring programs across all production suites.
Product Release Testing: Comprehensive characterization including sterility, mycoplasma, endotoxin, potency, identity, purity, and safety testing per USP, EP, and JP pharmacopeial standards. WuXi AppTec's integrated testing services support release testing for hundreds of client programs.
Stability Monitoring: Real-time and accelerated stability studies ensuring product integrity throughout the cryogenic cold chain from factory to patient bedside. Sartorius provides cryopreservation and cold chain monitoring solutions critical to this quality dimension.
Batch Disposition and Traceability: Complete chain-of-custody and chain-of-identity documentation from apheresis through final product release. Legend Biotech's proprietary tracking system ensures each autologous CARVYKTI dose is traceable from patient cell collection through infusion, meeting FDA requirements for 30-year record retention.
Raw Material Qualification: Comprehensive supplier auditing and lot-to-lot testing of critical raw materials including cell culture media (Gibco, Lonza), cytokines, viral vectors, and cryopreservation solutions. Thermo Fisher and Lonza provide certified raw materials with complete traceability documentation.
In-Process Control (IPC): Real-time monitoring of critical process parameters including cell viability, expansion rates, transduction efficiency, and sterility. Danaher/Cytiva's PAT platforms enable continuous monitoring throughout the manufacturing process, reducing the time between deviation detection and corrective action from days to minutes.
Environmental Monitoring: Continuous particle counting, microbial sampling, and HVAC validation across ISO 5 through ISO 8 cleanroom environments. Kite Pharma's four-facility network maintains stringent environmental monitoring programs across all production suites.
Product Release Testing: Comprehensive characterization including sterility, mycoplasma, endotoxin, potency, identity, purity, and safety testing per USP, EP, and JP pharmacopeial standards. WuXi AppTec's integrated testing services support release testing for hundreds of client programs.
Stability Monitoring: Real-time and accelerated stability studies ensuring product integrity throughout the cryogenic cold chain from factory to patient bedside. Sartorius provides cryopreservation and cold chain monitoring solutions critical to this quality dimension.
Batch Disposition and Traceability: Complete chain-of-custody and chain-of-identity documentation from apheresis through final product release. Legend Biotech's proprietary tracking system ensures each autologous CARVYKTI dose is traceable from patient cell collection through infusion, meeting FDA requirements for 30-year record retention.
2025-2026年哪些关键趋势正在改变CGT制造？
五大变革性趋势正在从根本上重塑2025-2026年的细胞与基因治疗制造格局。
制造垂直整合：细胞治疗公司正在投入数十亿美元建设自有内部产能。Kite Pharma的四个工厂网络、Legend Biotech可容纳10,000名患者的Raritan超级工厂，以及百时美施贵宝的多基地扩张，标志着从轻资产向重资产战略的范式转变。这一趋势压缩了纯CDMO的利润率，同时提高了治疗开发者的质量控制水平。
自动化和AI驱动制造：像Cytiva的Sefia系统这样的封闭式平台，有望将制造成本降低高达60%，同时提高一致性。GenScript/ProBio的关灯工厂和Thermo Fisher的自动化细胞处理平台进一步加速了这一转型。
地缘政治供应链重组：《生物安全法案》和贸易政策的演变引发了根本性的重新配置。Minaris Advanced Therapies从药明康德ATU业务剥离成立，以及药明康德随后专注于上游TIDES制造，就是这种重组的例证。公司正在投资国内产能并多元化供应商基础。
连续制造采用：行业正从批次处理转向病毒载体的连续处理，Lonza和Thermo Fisher引领基于灌流的连续制造平台开发。这些系统可将生产成本降低30-40%，同时提高产量。
床旁制造：分散式、基于医院的制造模式正在兴起，Lonza的Cocoon平台和Cytiva的自动化系统实现了现场细胞治疗生产。这可能通过将静脉到静脉时间从数周缩短到数天，从而改变自体治疗交付方式。
制造垂直整合：细胞治疗公司正在投入数十亿美元建设自有内部产能。Kite Pharma的四个工厂网络、Legend Biotech可容纳10,000名患者的Raritan超级工厂，以及百时美施贵宝的多基地扩张，标志着从轻资产向重资产战略的范式转变。这一趋势压缩了纯CDMO的利润率，同时提高了治疗开发者的质量控制水平。
自动化和AI驱动制造：像Cytiva的Sefia系统这样的封闭式平台，有望将制造成本降低高达60%，同时提高一致性。GenScript/ProBio的关灯工厂和Thermo Fisher的自动化细胞处理平台进一步加速了这一转型。
地缘政治供应链重组：《生物安全法案》和贸易政策的演变引发了根本性的重新配置。Minaris Advanced Therapies从药明康德ATU业务剥离成立，以及药明康德随后专注于上游TIDES制造，就是这种重组的例证。公司正在投资国内产能并多元化供应商基础。
连续制造采用：行业正从批次处理转向病毒载体的连续处理，Lonza和Thermo Fisher引领基于灌流的连续制造平台开发。这些系统可将生产成本降低30-40%，同时提高产量。
床旁制造：分散式、基于医院的制造模式正在兴起，Lonza的Cocoon平台和Cytiva的自动化系统实现了现场细胞治疗生产。这可能通过将静脉到静脉时间从数周缩短到数天，从而改变自体治疗交付方式。
What key trends are transforming CGT manufacturing in 2025-2026?
Five transformative trends are fundamentally reshaping the CGT manufacturing landscape in 2025-2026.
Vertical Integration of Manufacturing: Cell therapy companies are investing billions in proprietary internal capacity. Kite Pharma's four-facility network, Legend Biotech's 10,000-patient-capacity Raritan mega-plant, and Bristol Myers Squibb's multi-site expansion represent a paradigm shift from asset-light to asset-heavy strategies. This trend is compressing margins for pure-play CDMOs while increasing quality control for therapy developers.
Automation and AI-Driven Manufacturing: Closed-system platforms like Cytiva's Sefia system demonstrate the potential to reduce manufacturing labor costs by up to 60% while improving consistency. GenScript/ProBio's Lights-out factories and Thermo Fisher's automated cell processing platforms further accelerate this transformation.
Geopolitical Supply Chain Restructuring: The BIOSECURE Act and trade policy evolution have triggered fundamental reconfiguration. Minaris Advanced Therapies' formation from WuXi ATU's divestiture, and WuXi AppTec's subsequent focus on upstream TIDES manufacturing, exemplify this restructuring. Companies are investing in domestic capacity and diversifying supplier bases.
Continuous Manufacturing Adoption: The industry is transitioning from batch to continuous processing for viral vector production, with Lonza and Thermo Fisher leading development of perfusion-based continuous manufacturing platforms. These systems can reduce production costs by 30-40% while increasing throughput.
Point-of-Care Manufacturing: Decentralized, hospital-based manufacturing models are emerging, with Lonza's Cocoon platform and Cytiva's automated systems enabling on-site cell therapy production. This could transform autologous therapy delivery by reducing vein-to-vein times from weeks to days.
Vertical Integration of Manufacturing: Cell therapy companies are investing billions in proprietary internal capacity. Kite Pharma's four-facility network, Legend Biotech's 10,000-patient-capacity Raritan mega-plant, and Bristol Myers Squibb's multi-site expansion represent a paradigm shift from asset-light to asset-heavy strategies. This trend is compressing margins for pure-play CDMOs while increasing quality control for therapy developers.
Automation and AI-Driven Manufacturing: Closed-system platforms like Cytiva's Sefia system demonstrate the potential to reduce manufacturing labor costs by up to 60% while improving consistency. GenScript/ProBio's Lights-out factories and Thermo Fisher's automated cell processing platforms further accelerate this transformation.
Geopolitical Supply Chain Restructuring: The BIOSECURE Act and trade policy evolution have triggered fundamental reconfiguration. Minaris Advanced Therapies' formation from WuXi ATU's divestiture, and WuXi AppTec's subsequent focus on upstream TIDES manufacturing, exemplify this restructuring. Companies are investing in domestic capacity and diversifying supplier bases.
Continuous Manufacturing Adoption: The industry is transitioning from batch to continuous processing for viral vector production, with Lonza and Thermo Fisher leading development of perfusion-based continuous manufacturing platforms. These systems can reduce production costs by 30-40% while increasing throughput.
Point-of-Care Manufacturing: Decentralized, hospital-based manufacturing models are emerging, with Lonza's Cocoon platform and Cytiva's automated systems enabling on-site cell therapy production. This could transform autologous therapy delivery by reducing vein-to-vein times from weeks to days.
CGT制造商排名多久更新一次？
VerityRank每年在每个财年结束后更新其基因和细胞治疗制造商排名。当前排名反映了2025财年的数据，包括截至2025年12月31日的经审计财务报告、监管文件和制造现场认证。
在发生重大事件时会进行临时更新，包括重大设施收购或剥离（例如Minaris Advanced Therapies通过药明康德ATU-Minaris合并成立）、重大监管行动（FDA警告信、同意令或突破性制造批准）以及超过公司先前CGT制造足迹30%的重大产能扩张。
具有新兴制造能力的公司如果满足阈值标准，可能会被添加到观察名单中以备将来纳入：拥有GMP认证的生产设施、商业规模批次产能（>100批次/年）以及与至少一种FDA/EMA批准的CGT产品有直接制造关系。
下一次计划的全面更新将在2026财年业绩发布后于2027年第一季度发布，届时排名将纳入2026年全年制造数据、新设施认证和更新的监管合规记录。
订阅VerityRank通知以优先获取排名更新。
在发生重大事件时会进行临时更新，包括重大设施收购或剥离（例如Minaris Advanced Therapies通过药明康德ATU-Minaris合并成立）、重大监管行动（FDA警告信、同意令或突破性制造批准）以及超过公司先前CGT制造足迹30%的重大产能扩张。
具有新兴制造能力的公司如果满足阈值标准，可能会被添加到观察名单中以备将来纳入：拥有GMP认证的生产设施、商业规模批次产能（>100批次/年）以及与至少一种FDA/EMA批准的CGT产品有直接制造关系。
下一次计划的全面更新将在2026财年业绩发布后于2027年第一季度发布，届时排名将纳入2026年全年制造数据、新设施认证和更新的监管合规记录。
订阅VerityRank通知以优先获取排名更新。
How often are CGT manufacturer rankings updated?
VerityRank updates its gene and cell therapy manufacturer rankings annually following the completion of each fiscal year. The current rankings reflect data from the 2025 fiscal year, including audited financial reports, regulatory filings, and manufacturing site certifications through December 31, 2025.
Interim updates occur following material events including major facility acquisitions or divestitures (such as Minaris Advanced Therapies' formation through the WuXi ATU-Minaris merger), significant regulatory actions (FDA warning letters, consent decrees, or breakthrough manufacturing approvals), and major capacity expansions exceeding 30% of a company's prior CGT manufacturing footprint.
Companies with emerging manufacturing capabilities may be added to a watch list for future inclusion if they meet threshold criteria: ownership of GMP-certified production facilities, commercial-scale batch capacity (>100 batches/year), and direct manufacturing relationships with at least one FDA/EMA-approved CGT product.
The next scheduled comprehensive update will be published in Q1 2027 following the release of 2026 fiscal year results, at which point the rankings will incorporate full-year 2026 manufacturing data, new facility certifications, and updated regulatory compliance records.
Subscribe to VerityRank notifications for priority access to ranking updates.
Interim updates occur following material events including major facility acquisitions or divestitures (such as Minaris Advanced Therapies' formation through the WuXi ATU-Minaris merger), significant regulatory actions (FDA warning letters, consent decrees, or breakthrough manufacturing approvals), and major capacity expansions exceeding 30% of a company's prior CGT manufacturing footprint.
Companies with emerging manufacturing capabilities may be added to a watch list for future inclusion if they meet threshold criteria: ownership of GMP-certified production facilities, commercial-scale batch capacity (>100 batches/year), and direct manufacturing relationships with at least one FDA/EMA-approved CGT product.
The next scheduled comprehensive update will be published in Q1 2027 following the release of 2026 fiscal year results, at which point the rankings will incorporate full-year 2026 manufacturing data, new facility certifications, and updated regulatory compliance records.
Subscribe to VerityRank notifications for priority access to ranking updates.